Pages that link to "Q78409843"
Jump to navigation
Jump to search
The following pages link to Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment (Q78409843):
Displaying 50 items.
- Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions (Q26741320) (← links)
- Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments (Q26851694) (← links)
- Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma (Q27013785) (← links)
- Daclizumab therapy for multiple sclerosis (Q27022517) (← links)
- Defining Limits of Treatment with Humanized Neutralizing Monoclonal Antibody for West Nile Virus Neurological Infection in a Hamster Model (Q27480795) (← links)
- Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies (Q28084055) (← links)
- Immune Regulation of Antibody Access to Neuronal Tissues (Q28733365) (← links)
- Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption (Q30500905) (← links)
- Metastatic neurologic complications of non-Hodgkin's lymphoma (Q33210220) (← links)
- Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas (Q33361449) (← links)
- A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. (Q33411059) (← links)
- Biology and treatment of primary central nervous system lymphoma (Q33475480) (← links)
- Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease (Q33759799) (← links)
- Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. (Q33828585) (← links)
- Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. (Q33876476) (← links)
- Progress in central nervous system lymphomas. (Q33934406) (← links)
- Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment (Q33946604) (← links)
- Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence (Q33947639) (← links)
- Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation (Q34061575) (← links)
- Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma (Q34111789) (← links)
- Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity (Q34287001) (← links)
- Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report (Q34344942) (← links)
- B-lymphocyte-mediated delayed cognitive impairment following stroke. (Q35044819) (← links)
- Antibodies for the treatment of diffuse large cell lymphoma. (Q35206351) (← links)
- Intrathecal effects of daclizumab treatment of multiple sclerosis (Q35635127) (← links)
- Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies (Q35686137) (← links)
- Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome (Q35799389) (← links)
- Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma (Q35867843) (← links)
- Intraocular lymphoma: update on diagnosis and management (Q35892007) (← links)
- Imaging and Therapy with Rituximab Anti-CD20 Immunotherapy in an Animal Model of Central Nervous System Lymphoma (Q35914118) (← links)
- Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features (Q35964200) (← links)
- Management of primary intraocular lymphoma (Q35989747) (← links)
- Successful Treatment of Posttransplant EBV-Associated Lymphoma and Plasmacytoma Solely Localized to the CNS (Q36169107) (← links)
- Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route (Q36199725) (← links)
- Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment (Q36469191) (← links)
- Towards HIV-1 remission: potential roles for broadly neutralizing antibodies (Q36515149) (← links)
- International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future (Q36530118) (← links)
- Secondary central nervous system lymphoma (Q36574176) (← links)
- Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma (Q36584818) (← links)
- Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis (Q36639659) (← links)
- Treatment of CNS dissemination in systemic lymphoma (Q36749294) (← links)
- Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges (Q36761844) (← links)
- New approaches in primary central nervous system lymphoma (Q37088471) (← links)
- Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma (Q37149388) (← links)
- A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue (Q37183305) (← links)
- How I treat CNS lymphomas (Q37215118) (← links)
- Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience (Q37280734) (← links)
- Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy (Q37295494) (← links)
- First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma (Q37344959) (← links)
- Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options (Q37402645) (← links)